Transverse Myelitis (TM) is an autoimmune inflammatory disease of the central nervous system that is characterized by focal spinal cord demyelination and axonal injury. TM causes paralysis and other neurologic disabilities, but has limited treatment options due to a lack of understanding of its underlying mechanisms.
In a paper appearing online on September 22 in advance of print publication of the October 1 issue of the Journal of Clinical Investigation, Douglas Kerr and colleagues from Johns Hopkins find that levels of the cytokine IL-6 are selectively increased in cerebrospinal fluid from TM patients. The researchers show that elevated IL-6 levels alone are necessary and sufficient to mediate injury to both neuronal and glial cells, in a manner that is dependent on nitric oxide.
This is the first description of IL-6 as a mediator of neural injury. Further, high levels of IL-6 were directly correlated with tissue injury and clinical disability, suggesting that IL-6 may be an important biomarker of TM. This new data may aid in the development of effective therapies against TM and other inflammatory diseases of the central nervous system.
TITLE: Interleukin-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder Transverse Myelitis
AUTHOR CONTACT:
Douglas Kerr
Johns Hopkins University School of Medicine, Baltimore, MD USA
Phone: 410-955-3129; Fax: 410-502-6736; E-mail: dkerr@jhmi.edu
View the PDF of this article at: https://www.the-jci.org/article.php?id=25141
ONCOLOGY
HOW CAN SOMETHING AS BAD AS ARSENIC BE SO GOOD FOR CANCER?
It has been shown that two treatments for acute promyelocytic leukemia (APL), Arsenic trioxide and retinoic acid
'"/>
Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
22-Sep-2005